Kiser Tyree H, Jung Rose, MacLaren Robert, Fish Douglas N
Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
Pharmacotherapy. 2005 Dec;25(12):1736-45. doi: 10.1592/phco.2005.25.12.1736.
To evaluate diagnostic tests for heparin-induced thrombocytopenia (HIT), a serious drug reaction that can occur in patients receiving heparin, and to evaluate treatment with direct thrombin inhibitors-the only initial drug therapy that decreases the risk of thromboembolism associated with immune-mediated HIT.
Retrospective cohort study.
University teaching hospital.
Patients with HIT treated with argatroban or lepirudin between January 1, 2000, and December 31, 2003.
Patients were assessed for dosage and duration of argatroban or lepirudin therapy, HIT diagnostic tests, and clinically significant adverse events. Thirty-four patients received argatroban, 42 received lepirudin. Mean+/-SD doses of argatroban and lepirudin were 1.2+/-0.9 microg/kg/minute and 0.09+/-0.11 mg/kg/hour, respectively; both were 40% lower than the recommended doses. Mean duration of therapy was 10+/-9 days. Supratherapeutic activated partial thromboplastin times were observed in 30 (39%), 10 (13%) , and six (8%) of 76 patients on days 1, 2, and 3, respectively (p<0.0001). Clinically significant bleeding occurred in 6% of patients receiving argatroban and in 5% of those receiving lepirudin (p=0.99); all patients had an activated partial thromboplastin time of longer than 100 seconds. Although platelet-aggregation tests were ordered in 55 (72%) of 76 patients, they were not useful in 16 (29%) because of equivocal or contradictory results.
Due to supratherapeutic activated partial thromboplastin times, our patients often required doses of argatroban and lepirudin lower than those usually recommended. Thus, direct thrombin inhibitors should be started at low initial doses and titrated to target activated partial thromboplastin times to achieve appropriate efficacy and to avoid increasing the risk of bleeding. Platelet-aggregation tests were least useful for evaluating HIT. Appropriate diagnostic strategies should be used to avoid unnecessary drug use.
评估肝素诱导的血小板减少症(HIT)的诊断试验,HIT是一种可发生于接受肝素治疗患者的严重药物反应,并评估直接凝血酶抑制剂的治疗效果,直接凝血酶抑制剂是唯一可降低与免疫介导的HIT相关的血栓栓塞风险的初始药物治疗。
回顾性队列研究。
大学教学医院。
2000年1月1日至2003年12月31日期间接受阿加曲班或比伐卢定治疗的HIT患者。
评估患者阿加曲班或比伐卢定治疗的剂量和疗程、HIT诊断试验以及具有临床意义的不良事件。34例患者接受阿加曲班治疗,42例接受比伐卢定治疗。阿加曲班和比伐卢定的平均±标准差剂量分别为1.2±0.9微克/千克/分钟和0.09±0.11毫克/千克/小时;均比推荐剂量低40%。平均治疗疗程为10±9天。在76例患者中,分别有30例(39%)、10例(13%)和6例(8%)在第1、2和3天观察到活化部分凝血活酶时间超过治疗水平(p<0.0001)。接受阿加曲班治疗的患者中有6%发生具有临床意义的出血,接受比伐卢定治疗的患者中有5%发生出血(p=0.99);所有患者的活化部分凝血活酶时间均超过100秒。虽然76例患者中有55例(72%)进行了血小板聚集试验,但其中16例(29%)因结果不明确或相互矛盾而无诊断价值。
由于活化部分凝血活酶时间超过治疗水平,我们的患者常需要低于通常推荐剂量的阿加曲班和比伐卢定。因此,直接凝血酶抑制剂应从低初始剂量开始,并根据活化部分凝血活酶时间进行滴定,以达到适当疗效并避免增加出血风险。血小板聚集试验对评估HIT最无诊断价值。应采用适当的诊断策略以避免不必要的药物使用。